These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 843707)

  • 1. Role of tryptaminergic mechanisms in the elements of the behavioural syndrome evoked by tryptophan and a monoamine oxidase inhibitor [proceedings].
    Crow TJ; Deakin JF
    Br J Pharmacol; 1977 Mar; 59(3):461P. PubMed ID: 843707
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of tryptamine in the behavioural changes caused by a monoamine oxidase inhibitor and L-tryptophan [proceedings].
    Curzon G; Marsden CA
    Br J Pharmacol; 1977 Jun; 60(2):307P-308P. PubMed ID: 880472
    [No Abstract]   [Full Text] [Related]  

  • 3. Some observations on the behavioural and biochemical effects of L-tryptophan plus a monoamine oxidase inhibitor in immature rats [proceedings].
    Atterwill CK; Costain DW; Green AR
    Br J Pharmacol; 1979 May; 66(1):118P-119P. PubMed ID: 454914
    [No Abstract]   [Full Text] [Related]  

  • 4. The contribution of tryptamine to the behavioural effects of l-Tryptophan in tranylcypromine-treated rats.
    Marsden CA; Curzon G
    Psychopharmacology (Berl); 1978 Apr; 57(1):71-6. PubMed ID: 149328
    [No Abstract]   [Full Text] [Related]  

  • 5. The role of tryptamine in the behavioural effects of tranylcypromine + L-tryptophan.
    Marsden CA; Curzon G
    Neuropharmacology; 1979 Feb; 18(2):159-64. PubMed ID: 431783
    [No Abstract]   [Full Text] [Related]  

  • 6. Proceedings: The role of brain dopamine in the hyperactivity syndrome produced in rats after administration of L-tryptophan and a monoamine oxidase inhibitor.
    Grahame-Smith DG; Green AR
    Br J Pharmacol; 1974 Mar; 50(3):442P-443P. PubMed ID: 4853875
    [No Abstract]   [Full Text] [Related]  

  • 7. The effects of putative 5-hydroxytryptamine antagonists on the behaviour produced by administration of tranylcypromine and L-tryptophan or tranylcypromine and L-DOPA to rats.
    Deakin JF; Green AR
    Br J Pharmacol; 1978 Oct; 64(2):201-9. PubMed ID: 708990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time studies on the effects of tranylcypromine plus tryptophan on formation of tryptamine and 5-hydroxytryptamine in rat brain.
    Hay JL; McKim HR; Baker GB; Dewhurst WG
    Proc West Pharmacol Soc; 1982; 25():133-5. PubMed ID: 7122487
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacological studies on serotonin-mediated behaviour.
    Green AR
    J Physiol (Paris); 1981; 77(2-3):437-47. PubMed ID: 6457143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A role for brain protein in the process by which brain serotonin and certain other indolealkylamines produce behaviourally excitant effects in the rat.
    Grahame-Smith DG
    Clin Sci; 1972 Feb; 42(2):11P-12P. PubMed ID: 5058563
    [No Abstract]   [Full Text] [Related]  

  • 11. Indole metabolism and behavior in dog.
    Himwich WA; Davis JM; Forbes DJ; Glisson SN; Magnusson T; Stout MA; Trusty DM
    Biol Psychiatry; 1972 Feb; 4(1):51-63. PubMed ID: 5063122
    [No Abstract]   [Full Text] [Related]  

  • 12. Biochemical correlates of behavior in schizophrenic patients. Schizophrenic patients receiving tryptophan and methionine or methionine together with a monoamine oxidase inhibitor.
    Berlet HH; Matsumoto K; Pscheidt GR; Spaide J; Bull C; Himwich HE
    Arch Gen Psychiatry; 1965 Dec; 13(6):521-31. PubMed ID: 5841751
    [No Abstract]   [Full Text] [Related]  

  • 13. A comparison of the effects of some monoamine oxidase (MAO) inhibitors with 5-hydroxytryptophan (5-HTP) and dihydroxyphenylalanine (DOPA) on spinal synaptic activity.
    Anderson EG; Baker R; Banna N
    Proc West Pharmacol Soc; 1966; 9():40-1. PubMed ID: 5958499
    [No Abstract]   [Full Text] [Related]  

  • 14. The effects of monoamine oxidase inhibitors on spinal synaptic activity.
    Anderson EG; Baker RG; Banna NR
    J Pharmacol Exp Ther; 1967 Dec; 158(3):405-15. PubMed ID: 5299660
    [No Abstract]   [Full Text] [Related]  

  • 15. Acute versus chronic effects of serotonin uptake blockers on potentiation of the "serotonin syndrome".
    Hwang EC; Van Woert MH
    Commun Psychopharmacol; 1980; 4(2):161-7. PubMed ID: 7428337
    [No Abstract]   [Full Text] [Related]  

  • 16. Schizophrenic behavior and urinary tryptophan metabolites associated with cysteine given with and without a monoamine oxidase inhibitor (tranylcypromine).
    Spaide J; Tanimukai H; Ginther R; Bueno J; Himwich HE
    Life Sci; 1967 Mar; 6(5):551-60. PubMed ID: 4226702
    [No Abstract]   [Full Text] [Related]  

  • 17. [Behavioral modifications observed following repeated administrations of monoamine oxidase inhibitors].
    Goldwurm GF; Torrigiani G
    Riv Neurobiol; 1964; 10(4):Suppl:1099-106. PubMed ID: 5827089
    [No Abstract]   [Full Text] [Related]  

  • 18. Differential effects of monoamine oxidase inhibitors.
    Maickel RP; Rompalo AM; Cox RH
    Res Commun Chem Pathol Pharmacol; 1974 Aug; 8(4):727-30. PubMed ID: 4420181
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of tranylcypromine and pargyline on brain tryptamine.
    Tabakoff B; Moses F; Philips SR; Boulton AA
    Experientia; 1977 Mar; 33(3):380-1. PubMed ID: 870336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of butaclamol, a new neuroleptic, on serotoninergic mechanisms.
    Pugsley TA; Lippmann W
    J Pharm Pharmacol; 1977 Mar; 29(3):135-8. PubMed ID: 15075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.